Opinion|Videos|February 3, 2025
Setting Goals for Pediatric Atopic Dermatitis Treatment
Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such as Eczema Area and Severity Index (EASI)-75/90, Investigator Global Assessment (IGA), and itch scores alongside patient-reported outcomes to guide decisions while also considering disease severity and the impact of atopic comorbidities in treatment approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the goals of treatment for a patient with atopic dermatitis?
- How do treatment goals differ for atopic dermatitis in the pediatric population compared with adults?
- How do you leverage standard assessment tools such as EASI-75/90, IGA, and itch scores vs patient- and caregiver-reported outcomes?
- When considering disease severity and a treatment approach, how do you determine systemic eligibility in a pediatric patient?
- Does the presentation of atopic comorbidities dictate a treatment approach?
Advertisement
Related to this article
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.
In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.
New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
Jessica Nash, MD, IBCLC, shares strategies for assessing breastfeeding, identifying latch problems, and connecting families with lactation resources.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Michael Pistiner, MD, discusses how pediatricians can support food allergy management in schools through accurate diagnosis, emergency plans, and education.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Skipping newborn vitamin K tied to 47% higher infant bleeding risk
2
Breastfeeding essentials: Assessing latch and milk transfer
3
Maternal RSVpreF 78% effective against infant RSV hospitalization
4
Study identifies gaps in infant RSV immunization timing
5